HRS 2020: Boston Scientific’s Next-Gen LAAC Device Hits Targets In PINNACLE FLX Trial

The PINNACLE FLX trial of the next-generation WATCHMAN left atrial appendage closure device met its primary safety and effectiveness endpoints with a low adverse event rate of 0.5%.

Minimally invasive transcatheter closure treatment for left atrial appendage LLA with occluder, using a minimally invasive procedure treatment of structural heart disease

One-year results from the PINNACLE FLX trial show Boston Scientific Corp.’s WATCHMAN FLX system can safely and effectively close the left-atrial appendage closure device in patients with non-valvular atrial fibrillation.

Shephal Doshi of the Pacific Heart Institute in Santa Monica, CA, presented the 12-month follow-up data from the trial during the Heart Rhythm Society’s online scientific sessions on 8 May

More from Clinical Trials

More from R&D